Abiomed Inc. (NASDAQ:ABMD) reached a new 52-week high during trading on Thursday . The stock traded as high as $121.56 and last traded at $121.36, with a volume of 265,209 shares. The stock had previously closed at $118.58.

Several equities research analysts have commented on the company. Leerink Swann reiterated a “buy” rating on shares of Abiomed in a research note on Sunday, April 17th. Jefferies Group restated a “buy” rating on shares of Abiomed in a research report on Saturday, April 9th. Zacks Investment Research upgraded Abiomed from a “hold” rating to a “buy” rating and set a $106.00 price target for the company in a research report on Thursday, May 5th. Finally, Benchmark Co. restated a “buy” rating and issued a $145.00 price target on shares of Abiomed in a research report on Sunday, April 10th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $115.67.

The company’s 50-day moving average price is $112.55 and its 200-day moving average price is $96.91. The firm has a market cap of $5.15 billion and a PE ratio of 127.93.

Abiomed (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. The firm earned $103 million during the quarter, compared to analyst estimates of $97.23 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The business’s quarterly revenue was up 40.3% compared to the same quarter last year. On average, equities analysts anticipate that Abiomed Inc. will post $1.17 EPS for the current fiscal year.

In other news, COO David M. Weber sold 4,342 shares of the business’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $96.97, for a total value of $421,043.74. Following the completion of the sale, the chief operating officer now owns 100,159 shares of the company’s stock, valued at approximately $9,712,418.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Henri A. Termeer sold 25,866 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $118.70, for a total transaction of $3,070,294.20. Following the completion of the sale, the director now directly owns 325,778 shares of the company’s stock, valued at approximately $38,669,848.60. The disclosure for this sale can be found here.

Several large investors recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in Abiomed by 4.3% in the fourth quarter. Principal Financial Group Inc. now owns 262,842 shares of the company’s stock valued at $23,729,000 after buying an additional 10,851 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Abiomed by 20.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 75,064 shares of the company’s stock valued at $6,778,000 after buying an additional 12,987 shares during the last quarter. Redwood Investments LLC increased its stake in Abiomed by 19.1% in the fourth quarter. Redwood Investments LLC now owns 22,724 shares of the company’s stock valued at $2,052,000 after buying an additional 3,639 shares during the last quarter. Wells Fargo & Company MN increased its stake in Abiomed by 396.1% in the fourth quarter. Wells Fargo & Company MN now owns 179,883 shares of the company’s stock valued at $16,240,000 after buying an additional 143,624 shares during the last quarter. Finally, KBC Group NV increased its stake in Abiomed by 47.1% in the fourth quarter. KBC Group NV now owns 16,302 shares of the company’s stock valued at $1,472,000 after buying an additional 5,220 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.